Enzo Biochem (ENZ) 10-Q 10 Jun 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2019	Jun. 01, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		47,556,807
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Document Period End Date	Apr. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ex Transition Period	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Current assets:
Cash and cash equivalents	$ 64,052	$ 60,041
Accounts receivable, net of allowances	11,441	13,147
Inventories	7,595	7,278
Prepaid expenses and other	2,635	2,734
Total current assets	85,723	83,200
Property, plant and equipment, net	14,244	7,636
Goodwill	7,452	7,452
Intangible assets, net	1,128	1,886
Other assets, including restricted cash of $750 at April 30, 2019	2,453	1,486
Total assets	111,000	101,660
Current liabilities:
Accounts payable – trade	6,423	9,516
Accrued liabilities	8,457	10,054
Other current liabilities	392	616
Total current liabilities	15,272	20,186
Loan payable, net	4,235
Other liabilities	494	353
Total liabilities	20,001	20,539
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,556,807 at April 30, 2019 and 47,182,254 at July 31, 2018	476	472
Additional paid-in capital	332,490	330,770
Accumulated deficit	(244,345)	(252,221)
Accumulated other comprehensive income	2,378	2,100
Total stockholders’ equity	90,999	81,121
Total liabilities and stockholders’ equity	$ 111,000	$ 101,660

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Other assets, including restricted cash (in Dollars)	$ 750
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	47,556,807	47,182,254
Common Stock, shares outstanding	47,556,807	47,182,254

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Revenues	$ 19,662,000	$ 25,230,000	$ 60,249,000	$ 78,258,000
Operating costs, expenses and legal settlements, net:
Cost of Revenues	14,360,000	14,557,000	43,347,000	45,595,000
Research and development	781,000	799,000	2,342,000	2,358,000
Selling, general and administrative	10,920,000	11,021,000	33,387,000	32,975,000
Legal fee expense	257,000	1,651,000	2,700,000	3,782,000
Legal settlements, net	(28,925,000)		(28,925,000)
Total operating costs, expenses and legal settlements, net	(2,607,000)	28,028,000	52,851,000	84,710,000
Operating income (loss)	22,269,000	(2,798,000)	7,398,000	(6,452,000)
Other income (expense):
Interest	258,000	227,000	759,000	569,000
Other	70,000	17,000	249,000	86,000
Foreign exchange (loss) gain	(332,000)	(462,000)	(530,000)	143,000
Income (loss) before income taxes	22,265,000	(3,016,000)	7,876,000	(5,654,000)
Benefit for income taxes	0	0	0	1,097,000
Net income (loss)	$ 22,265,000	$ (3,016,000)	$ 7,876,000	$ (4,557,000)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.47	$ (0.06)	$ 0.17	$ (0.10)
Diluted (in Dollars per share)	$ 0.47	$ (0.06)	$ 0.17	$ (0.10)
Weighted average common shares outstanding:
Basic (in Shares)	47,452	47,073	47,259	46,895
Diluted (in Shares)	47,555	47,073	47,364	46,895

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Net income (loss)	$ 22,265	$ (3,016)	$ 7,876	$ (4,557)
Other comprehensive gain (loss):
Foreign currency translation adjustments	206	329	278	(166)
Comprehensive income (loss)	$ 22,471	$ (2,687)	$ 8,154	$ (4,723)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance at Jul. 31, 2017	$ 465	$ 328,294	$ (241,900)	$ 2,013		$ 88,872
Balance (in Shares) at Jul. 31, 2017	46,506,176
Net income (loss) for the period ended			(4,557)			(4,557)
Cashless options exercise	$ 4	1,010			$ (1,014)
Cashless options exercise (in Shares)	340,898				106,911
Vesting of restricted stock (in Shares)	2,562
Exercise of stock options	$ 3	828				831
Exercise of stock options (in Shares)	274,726
Share-based compensation charges		617				617
Issuance of common stock and treasury stock for employee 401(k) plan match		(232)			$ 1,014	782
Issuance of common stock and treasury stock for employee 401(k) plan match (in Shares)	37,580				(106,911)
Foreign currency translation adjustments				(166)		(166)
Balance at Apr. 30, 2018	$ 472	330,517	(246,457)	1,847		86,379
Balance (in Shares) at Apr. 30, 2018	47,161,942
Balance at Jan. 31, 2018	$ 471	330,425	(243,441)	1,518	$ (1,014)	87,959
Balance (in Shares) at Jan. 31, 2018	47,077,840				106,911
Net income (loss) for the period ended			(3,016)			(3,016)
Cashless options exercise	$ 4	(4)
Vesting of restricted stock (in Shares)	500
Exercise of stock options	$ (3)	124				121
Exercise of stock options (in Shares)	46,022
Share-based compensation charges		204				204
Issuance of common stock and treasury stock for employee 401(k) plan match		(232)			$ 1,014	782
Issuance of common stock and treasury stock for employee 401(k) plan match (in Shares)	37,580				(106,911)
Foreign currency translation adjustments				329		329
Balance at Apr. 30, 2018	$ 472	330,517	(246,457)	1,847		86,379
Balance (in Shares) at Apr. 30, 2018	47,161,942
Balance at Jul. 31, 2018	$ 472	330,770	(252,221)	2,100		81,121
Balance (in Shares) at Jul. 31, 2018	47,182,254
Net income (loss) for the period ended			7,876			7,876
Vesting of restricted stock (in Shares)	986
Exercise of stock options	$ 1	166				$ 167
Exercise of stock options (in Shares)	34,719					238,230
Share-based compensation charges		725				$ 725
Net issuance of common stock for options exercised by Directors (in Shares)	23,376
Issuance of common stock and treasury stock for employee 401(k) plan match	$ 3	829				832
Issuance of common stock and treasury stock for employee 401(k) plan match (in Shares)	315,472
Foreign currency translation adjustments				278		278
Balance at Apr. 30, 2019	$ 476	332,490	(244,345)	2,378		90,999
Balance (in Shares) at Apr. 30, 2019	47,556,807
Balance at Jan. 31, 2019	$ 472	331,463	(266,610)	2,172		67,497
Balance (in Shares) at Jan. 31, 2019	47,241,335
Net income (loss) for the period ended			22,265			22,265
Exercise of stock options	$ 1	72				73
Share-based compensation charges		199				199
Net issuance of common stock for options exercised by Directors		(73)				(73)
Issuance of common stock and treasury stock for employee 401(k) plan match	$ 3	829				832
Issuance of common stock and treasury stock for employee 401(k) plan match (in Shares)	315,472
Foreign currency translation adjustments				206		206
Balance at Apr. 30, 2019	$ 476	$ 332,490	$ (244,345)	$ 2,378		$ 90,999
Balance (in Shares) at Apr. 30, 2019	47,556,807

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Cash flows from operating activities:
Net income (loss)	$ 7,876	$ (4,557)
Adjustments to reconcile net income (loss) to net cash provided by(used in) operating activities:
Depreciation and amortization of property, plant and equipment	1,631	1,608
Amortization of intangible assets	741	742
Share-based compensation charges	725	617
Accrual for share-based 401(k) employer match expense	650	630
Foreign exchange loss (gain)	461	(149)
Changes in operating assets and liabilities:
Accounts receivable	1,605	756
Inventories	(456)	(257)
Prepaid expenses and other assets	(36)	(585)
Accounts payable – trade	(3,363)	(2,126)
Accrued liabilities, other current liabilities and other liabilities	(1,853)	2,846
Total adjustments	105	4,082
Net cash provided by (used in) operating activities	7,981	(475)
Cash flows from investing activities:
Capital expenditures	(7,554)	(1,626)
Security deposits and other		(51)
Net cash used in investing activities	(7,554)	(1,677)
Cash flows from financing activities:
Proceeds from borrowing under mortgage loan	4,500
Repayments under loans and capital lease obligations	(244)	(299)
Costs to obtain mortgage loan	(72)
Proceeds from exercise of stock options	166	831
Net cash provided by financing activities	4,350	532
Effect of exchange rate changes on cash and cash equivalents	(16)	9
Increase (decrease) in cash and cash equivalents	4,761	(1,611)
Cash and cash equivalents - beginning of period	60,041	64,167
Cash and cash equivalents - end of period	64,802	62,556
The composition of cash and cash equivalents and restricted cash is as follows:
Cash and cash equivalents	64,052	62,556
Restricted cash included in other assets	750
Total cash and cash equivalents (including restricted cash)	$ 64,802	$ 62,556

Basis of Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2019
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics, Enzo Realty LLC and Enzo Realty II LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2019, the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended April 30, 2019 and 2018, the consolidated statements of cash flows for the nine months ended April 30, 2019 and 2018 and the consolidated statements of stockholders’ equity for the nine months ended April 30, 2019 and 2018 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted as permitted under rules promulgated by the Securities and Exchange Commission. The interim statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2018 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2018 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2019. Effect of New Accounting Pronouncements Adoption of New Accounting Standards On August 1, 2018, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (“FASB”) on revenue recognition using the full retrospective method. This new accounting standard outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. This standard supersedes existing revenue recognition requirements and eliminates most industry-specific revenue recognition guidance from GAAP. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to when control of goods or services are transferred to its customers. As a result of the Company’s adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to patient responsibility, are now considered an implicit price concession in determining net revenues from clinical services. Accordingly, the Company reports estimated uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues, when historically these amounts were classified and separately reported as a provision for uncollectible accounts receivable. The adoption of this standard has no impact on revenues reported for life sciences products. The adoption of this new accounting standard resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. For further details, see Note 3. The impact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in the table below: As Adjustment for New Reclassification As Restated Consolidated Statements of Operations for the three months ended April 30, 2018: Total Revenues $25,630 $(400) — $25,230 Provision for uncollectible accounts receivable 396 (400) $4 — Selling, general and administrative expenses 11,025 — (4) 11,021 Net loss $(3,016) — — $(3,016) Consolidated Statements of Operations for the nine months ended April 30, 2018: Total Revenues 80,258 (2,000) 78,258 Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Selling, general and administrative expenses 32,986 — (11) 32,975 Net loss (4,557) — — (4,557) Consolidated Statements of Cash Flows April 30, 2018: Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Changes in operating assets and liabilities: Accounts receivable (1,233) 2,000 (11) 756 Consolidated balance sheet July 31, 2018: Accounts receivable 15,815 (2,523) — 13,292 Less: Allowance for doubtful accounts 2,668 (2,523) — 145 Accounts receivable, net of allowance for doubtful accounts 13,147 — — 13,147 On August 1, 2018, the Company adopted a new accounting standard issued by FASB which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard requires that amendments in the update be applied prospectively to an award modified on or after the adoption date. For the foreseeable future, any excess income tax benefits or deficiencies from stock-based compensation, which would be recognized as discrete items within income tax expense rather than additional paid in capital, will be offset by an equivalent adjustment to the deferred tax valuation allowance. Accordingly, adoption of this standard had no impact on our reported operations. Pronouncements Issued but Not Yet Adopted In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842), In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 33% and 40% of Clinical Services net revenue for the three months ended April 30, 2019 and 2018 respectively, and 39% for the nine months ended April 30, 2019 and 2018. As of April 30, 2019, other than the Medicare program, one provider whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 14% of Clinical Services net receivables. As of July 31, 2018, other than the Medicare program, three providers whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 29% of Clinical Services net receivables. Income Taxes The provision for income taxes and the effective tax rates for the three months ended April 30, 2019 and 2018 is $0. The provision (benefit) for income taxes for the nine months ended April 30, 2019 and 2018 is $0 and ($1,097), respectively. The effective tax rate for the nine months ended April 30, 2018 was (19.4%). The primary differences between the Company’s effective tax rates and the statutory rates for the three and nine months ended April 30, 2019 and 2018 are due to the utilization of net operating losses for which a full valuation allowance was maintained and for a tax benefit recorded in the nine month period ended April 30, 2018 of $1.1 million. The $1.1 million tax benefit in the 2018 period is due to the Tax Act, signed into law December 22, 2017, in which the legislation provided for a credit for alternative minimum taxes (AMT) paid in prior periods. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets.

Net income (loss) per share

Net income (loss) per share	9 Months Ended
	Apr. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three months ended April 30, 2018 and nine months ended April 30, 2018 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and nine months ended April 30, 2018, approximately 431,000, and 694,000, respectively of potential common shares (“in the money options”) and unvested restricted stock were excluded from the calculation of diluted earnings per share. For the three and nine months ended April 30, 2019, the effect of approximately 1,640,000 and 1,541,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2018, the effect of approximately 581,000 and 194,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Apr. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3 – Revenue Recognition Clinical Services Revenue Net revenues in the Company’s clinical services business accounted for 63% and 72% of the Company’s total net revenues for the nine months ended April 30, 2019 and 2018, respectively and are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratories and will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers, government payers, client payers and patients as described below. Contracts with customers in our laboratory services business do not contain a financing component, based on the typically limited period of time between performance of services and collection of consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessions as well as the collectability of the transaction based on the patient intent and ability to pay. The Company uses the expected value method in estimating the amount of the variability included in the transaction price. The following are descriptions of our laboratory services business portfolios: Third party payers and Health Maintenance Organizations (HMO’s) Reimbursements from third party payers, primarily healthcare insurers, and HMO’s are based on negotiated fee-for-service schedules. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement. Collection of the consideration the Company expects to receive is normally a function of providing complete and correct billing information to these third party payers within the various filing deadlines, and typically occurs within 60 to 90 days of billing. Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, will reserve accordingly for the billing. Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payers in interpretations, requirements, and “conditions of participation” in various programs. Government Payer - Medicare Reimbursements from Medicare are based on fee-for-service schedules set by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historical collection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement. Collection of consideration the Company expects to receive is normally a function of providing the complete and correct billing information within the various filing deadlines and typically occurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordingly for the billing. Patient self-pay Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based on fees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Patient billings are generally fully reserved for when the related billing reaches 210 days outstanding. Balances are automatically written off when they are sent to collection agencies. Allowances are further adjusted for estimated recoveries of amounts sent to collection agencies based on historical collection experience, which is regularly monitored. Collection of consideration the Company expects to receive typically occurs within 180 days of billing. The following table represents clinical services net revenues and percentages by type of customer: Three months Three months Revenue category Third-party payer $ 5,799 50 % $ 9,965 56 % Medicare 2,634 22 2,858 16 Patient self-pay 1,881 16 2,047 12 HMO’s 1,437 12 2,867 16 Total $ 11,751 100 % $ 17,737 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 20,213 53 % $ 32,726 59 % Medicare 7,724 20 9,073 16 Patient self-pay 5,652 15 5,689 10 HMO’s 4,459 12 8,513 15 Total $ 38,048 100 % $ 56,001 100 % For the three and nine months ended April 30, 2019 and 2018, all of the Company’s clinical services were provided within the United States. Products Revenue and royalty income Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. Royalty income is based on net sales of the Company’s licensed products by a third party. We recognize royalty income in the period the sales occur based on third party evidence received. During the three and nine months ended April 30, 2019 there was no royalty income. For the three and nine months ended April 30, 2018, royalty income was $78 and $639, respectively. Products revenue by geography is as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 United States $ 4,585 $ 3,987 $ 12,570 $ 11,500 Europe 1,620 1,529 4,370 4,422 Rest of the world 1,706 1,899 5,261 5,578 Total $ 7,911 $ 7,415 $ 22,201 $ 21,500

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	9 Months Ended
	Apr. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 4 - Supplemental disclosure for statement of cash flows For the nine months ended April 30, 2019 and 2018, tax on capital paid by the Company were $94 and $65, respectively. For the nine months ended April 30, 2019 and 2018, interest paid by the Company was $138 and $61, respectively. During the nine months ended April 30, 2019, there was a total of $381 in capital lease agreements. During the nine months ended April 31, 2018, the Company did not enter into any material capital lease agreements. During the nine months ended April 30, 2019, certain directors and officers of the Company exercised 203,511 stock options in a non-cash transaction. The officers and directors received 23,376 net shares of common stock. The Company did not receive any proceeds from this exercise. The net shares issued represent the difference between the fair market value of the options on the date of exercise less the strike price cost to exercise the options. During the nine months ended April 30, 2019 the Company issued common stock in connection with its share based 401(k) employer match in the amount of $832. For the 2018 period, the Company issued shares of common stock in the amount of $782.

Inventories

Inventories	9 Months Ended
	Apr. 30, 2019
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 5 – Inventories Inventories consist of the following: April 30, July 31, Raw materials $ 895 $ 754 Work in process 2,480 2,174 Finished products 4,220 4,350 $ 7,595 $ 7,278

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6 – Goodwill and intangible assets At April 30, 2019 and July 31, 2018, the Company has goodwill of $7,452 allocated to the Clinical Services reporting unit. The Company’s change in the carrying amount of intangible assets, all in the Products segment is as follows: Gross Accumulated Amortization Net July 31, 2018 $ 27,347 $ (25,461 ) $ 1,886 Amortization expense — (741 ) (741 ) Foreign currency translation (110 ) 93 (17 ) April 30, 2019 $ 27,237 $ (26,109 ) $ 1,128 Intangible assets, all finite lived, consist of the following: April 30, 2019 July 31, 2018 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,992 ) $ 35 $ 11,027 $ (10,980 ) $ 47 Customer relationships 11,745 (10,652 ) 1,093 11,836 (9,997 ) 1,839 Website and acquired content 1,008 (1,008 ) — 1,008 (1,008 ) — Licensed technology and other 483 (483 ) — 483 (483 ) — Trademarks 2,974 (2,974 ) — 2,993 (2,993 ) — Total $ 27,237 $ (26,109 ) $ 1,128 $ 27,347 $ (25,461 ) $ 1,886 At April 30, 2019, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8 -15 years 1 year Other intangibles 10 years 4 years At April 30, 2019, the weighted average remaining useful life of intangible assets is approximately one year.

Loan Payable

Loan Payable	9 Months Ended
	Apr. 30, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 - Loan Payable In connection with the purchase of our new facility, on November 27, 2018, a wholly-owned subsidiary (the ““mortgagor subsidiary”) of the Company entered into a Fee Mortgage and Security Agreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement provides for a loan of $4,500 for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage payments of principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balance of unamortized debt issuance cost was $69 at April 30, 2019. At April 30, 2019, the balance owed by the subsidiary under the mortgage agreement was $4.4 million. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of April 30, 2019. The mortgage agreement includes affirmative and negative covenants and events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgage includes certain financial covenants. As of April 30, 2019, required financial covenants have been met. We assumed from the seller an operating lease for a current tenant at the facility which runs to December 2019. Rental income from the assumed lease is included in other income. Minimum future annual principal payments under the mortgage agreement as of April 30, 2019, are as follows: April 30, 2020 $ 134 2021 142 2022 149 2023 157 2024 165 Thereafter 3,691 4,438 Less: Current portion (134 ) Unamortized mortgage costs (69 ) Mortgage loan, non-current, net $ 4,235

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Apr. 30, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 8 – Accrued Liabilities Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 4,848 $ 4,870 Professional fees 592 811 Legal 167 2,121 Other 2,850 2,252 $ 8,457 $ 10,054

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity Offering SM On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017. During the nine months ended April 30, 2019 and 2018, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation On January 14, 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan to increase the number of shares available for issuance by 2,000,000 bringing the total number of shares available for award under the 2011 Plan to 5,000,000. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2019 2018 2019 2018 Stock options $ 197 $ 202 $ 718 $ 609 Restricted stock 2 2 7 8 $ 199 $ 204 $ 725 $ 617 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2019 2018 2019 2018 Selling, general and administrative $ 199 $ 204 $ 725 $ 617 $ 199 $ 204 $ 725 $ 617 No excess tax benefits were recognized during the nine month periods ended April 30, 2019 and 2018. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2019: Options Weighted Weighted Aggregate Outstanding at July 31, 2018 1,882,116 $ 4.96 Awarded 712,821 2.81 Exercised (238,230 ) 2.69 $ 117 Cancelled or expired (3,500 ) 5.86 Outstanding at end of period 2,353,207 4.53 3.1 years $ 496 Exercisable at end of period 1,215,231 5.24 1.0 years $ 22 As of April 30, 2019, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1.2 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is seventeen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. During the three months ended April 30, 2019 certain directors and officers of the Company exercised 203,511 stock options in non-cash transactions. The officers and directors received 23,376 net shares of common stock. The Company did not receive any proceeds from this exercise. The net shares issued represent the difference between the fair market value of the options on the date of exercise less the strike price cost to exercise the options. Performance Stock Units To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company granted long-term incentive awards in the form of time based stock options and performance-based restricted stock units (“Performance Stock Units” or “PSUs”). The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group. During fiscal year 2018 and 2019, the Company awarded PSUs to its executive officers, this award provides for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. As of April 30, 2019, the Company did not accrue any compensation expense for these PSU’s as the three-year performance period has just begun and achievement of the growth goals is currently not probable. The following table summarizes PSU’s granted: Period Total Fair Market Value 7/31/2018 32,000 $ 141 1/31/2019 80,500 $ 225 Restricted Stock Awards The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2019, there were 1,628 shares of unvested restricted stock which have a weighted average award price of $6.00 per share. As of April 30, 2019, there was approximately $10 of unrecognized compensation cost related to these unvested shares of restricted stock to be recognized over a weighted average remaining period of approximately twenty-one months. There were no awards made during the nine months ended April 30, 2019. During the nine months ended April 30, 2019, 985 restricted stock awards vested whose fair value was approximately $4. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,222,000 shares as of April 30, 2019. During the nine months ended April 30, 2019, the Company contributed $832 to match its employees’ 401(k) contributions by issuing 315,472 shares of its common stock representing the fair value of the shares at the match date, and adjusted common stock and additional paid in capital by the same amount. During the nine months ended April 30, 2018, the Company contributed $782 to match its employees’ 401(k) contributions with 106,911 shares of treasury stock and by issuing 37,580 shares of its common stock, representing the fair value of the shares at the match date, and adjusted treasury stock, common stock and additional paid in capital by the same amount.

Segment reporting

Segment reporting	9 Months Ended
	Apr. 30, 2019
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 10 – Segment reporting The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal fee expense specific to other segments’ activities have been allocated to those segments. Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment and expenses related to an investigation within the Clinical Services segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 11,751 $ 7,911 — — $ 19,662 Operating costs, expenses and legal settlements, net: Cost of revenues 10,963 3,397 — — 14,360 Research and development 31 527 $ 223 — 781 Selling, general and administrative 5,960 2,923 — $ 2,037 10,920 Legal fee expense 35 16 — 206 257 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 16,989 (22,062 ) 223 2,243 (2,607 ) Operating income (loss) (5,238 ) 29,973 (223 ) (2,243 ) 22,269 Other income (expense): Interest (18 ) 19 — 257 258 Other 6 — — 64 70 Foreign exchange loss — (332 ) — — (332 ) Income (loss) before income taxes $ (5,250 ) $ 29,660 $ (223 ) $ (1,922 ) $ 22,265 Depreciation and amortization included above $ 440 $ 340 $ — $ 58 $ 838 Share-based compensation included in above: Selling, general and administrative 40 24 — 135 199 Total $ 40 $ 24 $ — $ 135 $ 199 Capital expenditures $ 120 $ 446 $ — $ — $ 566 Three months ended April 30, 2018 Clinical Products Therapeutics Other Consolidated Revenues $ 17,737 $ 7,493 — — $ 25,230 Operating costs and expenses: Cost of revenues 10,995 3,562 — — 14,557 Research and development — 576 $ 223 — 799 Selling, general and administrative 6,252 2,970 — $ 1,799 11,021 Legal fee expense 25 19 — 1,607 1,651 Total operating costs and expenses 17,272 7,127 223 3,406 28,028 Operating income (loss) 465 366 (223 ) (3,406 ) (2,798 ) Other income (expense): Interest (22 ) 12 — 237 227 Other 15 2 — — 17 Foreign exchange loss — (462 ) — — (462 ) Income (loss) before income taxes $ 458 $ (82 ) $ (223 ) $ (3,169 ) $ (3,016 ) Depreciation and amortization included above $ 437 $ 358 $ — $ 20 $ 815 Share-based compensation included in above: Selling, general and administrative 26 17 — 161 204 Total $ 26 $ 17 $ — $ 161 $ 204 Capital expenditures $ 465 $ 96 $ — $ — $ 561 Nine months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 38,048 $ 22,201 — — $ 60,249 Operating costs, expenses and legal settlements, net: Cost of revenues 32,956 10,391 — — 43,347 Research and development 31 1,645 $ 666 — 2,342 Selling, general and administrative 18,220 8,828 — $ 6,339 33,387 Legal fee expense 109 24 — 2,567 2,700 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 51,316 (8,037 ) 666 8,906 52,851 Operating income (loss) (13,268 ) 30,238 (666 ) (8,906 ) 7,398 Other income (expense): Interest (51 ) 49 — 761 759 Other 17 — — 232 249 Foreign exchange loss (gain) — (530 ) — — (530 ) (Loss) income before income taxes $ (13,302 ) $ 29,757 $ (666 ) $ (7,913 ) $ 7,876 Depreciation and amortization included above $ 1,217 $ 1,025 $ — $ 130 $ 2,372 Share-based compensation included in above: Selling, general and administrative 118 74 — 533 725 Total $ 118 $ 74 $ — $ 533 $ 725 Capital expenditures $ 883 $ 524 $ — $ 6,147 $ 7,554 Nine months ended April 30, 2018 Clinical Products Therapeutics Other Consolidated Revenues $ 56,001 $ 22,257 — — $ 78,258 Operating costs and expenses: Cost of revenues 34,767 10,828 — — 45,595 Research and development — 1,690 $ 668 — 2,358 Selling, general and administrative 18,454 8,476 — $ 6,045 32,975 Legal fee expense 46 47 — 3,689 3,782 Total operating costs and expenses 53,267 21,041 668 9,734 84,710 Operating income (loss) 2,734 1,216 (668 ) (9,734 ) (6,452 ) Other income (expense): Interest (70 ) 35 — 604 569 Other 32 10 — 44 86 Foreign exchange loss — 143 — — 143 Income (loss) before income taxes $ 2,696 $ 1,404 $ (668 ) $ (9,086 ) $ (5,654 ) Depreciation and amortization included above $ 1,254 $ 1,039 $ — $ 57 $ 2,350 Share-based compensation included in above: Selling, general and administrative 86 61 — 470 617 Total $ 86 $ 61 $ — $ 470 $ 617 Capital expenditures $ 1,459 $ 167 $ — $ — $ 1,626

Contingencies

Contingencies	9 Months Ended
	Apr. 30, 2019
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 11 – Contingencies There are three cases that are on appeal, which were originally brought by the Company in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court entered summary judgment against the Company that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. The Company appealed the Court’s final judgment of invalidity in those cases to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”), which were subsequently consolidated (“the Consolidated Appeals”). The Federal Circuit heard oral argument in the Consolidated Appeals on January 7, 2019, but it has not issued a ruling or opinion. In the Consolidated Appeals, the Company has asked the Federal Circuit to reverse the Court’s grants of final and summary judgment of invalidity of the asserted claims of the ‘180 and ‘405 patents and to remand the cases against Abbott, Becton Dickinson, and Roche to the Court. In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ‘180 and ‘197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the Hologic III matter regarding the ‘581 Patent that involved both Hologic and Grifols; Hologic withdrew from Enzo’s Federal Circuit appeal of the Patent Trial and Appeal Board’s adverse rulings in two inter partes Enzo Biochem, Inc. (the “Company”), along with its subsidiaries Enzo Life Sciences, Inc. entered into a Settlement Agreement as of February 5,2019 (the “Agreement) with Roche Diagnostics GmbH and Roche Molecular Systems, Inc. (together, “Roche”) with respect to an action between the Company and Roche before the U.S. District Court, Southern District of New York, Case No 04-CV4046. Roche agreed to pay the Company $21 million in settlement pursuant to the Agreement. The Company received $19.4 million net of attorney contingency payments. This settlement does not affect Enzo’s civil action for patent infringement against Roche in the U.S. District Court for the State of Delaware, Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et al., civil action No. 12 cv-00106, which remains pending on appeal. Enzo Biochem, Inc. (the “Company”), along with its subsidiaries Enzo Life Sciences, Inc. entered into a settlement and license agreement as of April 16, 2019 (the “Agreement”) with Hologic, Inc. (“Hologic”), Grifols, S.A., and Grifols Diagnostic Solutions Inc. (together, “Grifols”) to settle all outstanding patent disputes among the parties. The terms of the agreement include one-time payments totaling $14 million to Enzo in exchange for fully paid-up, worldwide licenses to Hologic and Grifols. The Company received $9.5 million net of attorney contingency payments. There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations. As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputes these claims and has formally sent legal appeal letters to the payer. At this time, the Company is unable to determine the probability of the outcome of these appeals or reasonably estimate a range of potential losses associated with this claim.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of New Accounting Standards On August 1, 2018, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (“FASB”) on revenue recognition using the full retrospective method. This new accounting standard outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. This standard supersedes existing revenue recognition requirements and eliminates most industry-specific revenue recognition guidance from GAAP. The core principle of the revenue recognition standard is to require an entity to recognize as revenue the amount that reflects the consideration which it expects to be entitled to when control of goods or services are transferred to its customers. As a result of the Company’s adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to patient responsibility, are now considered an implicit price concession in determining net revenues from clinical services. Accordingly, the Company reports estimated uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore as a reduction in net revenues, when historically these amounts were classified and separately reported as a provision for uncollectible accounts receivable. The adoption of this standard has no impact on revenues reported for life sciences products. The adoption of this new accounting standard resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. For further details, see Note 3. The impact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in the table below: As Adjustment for New Reclassification As Restated Consolidated Statements of Operations for the three months ended April 30, 2018: Total Revenues $25,630 $(400) — $25,230 Provision for uncollectible accounts receivable 396 (400) $4 — Selling, general and administrative expenses 11,025 — (4) 11,021 Net loss $(3,016) — — $(3,016) Consolidated Statements of Operations for the nine months ended April 30, 2018: Total Revenues 80,258 (2,000) 78,258 Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Selling, general and administrative expenses 32,986 — (11) 32,975 Net loss (4,557) — — (4,557) Consolidated Statements of Cash Flows April 30, 2018: Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Changes in operating assets and liabilities: Accounts receivable (1,233) 2,000 (11) 756 Consolidated balance sheet July 31, 2018: Accounts receivable 15,815 (2,523) — 13,292 Less: Allowance for doubtful accounts 2,668 (2,523) — 145 Accounts receivable, net of allowance for doubtful accounts 13,147 — — 13,147 On August 1, 2018, the Company adopted a new accounting standard issued by FASB which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Adoption of this standard requires that amendments in the update be applied prospectively to an award modified on or after the adoption date. For the foreseeable future, any excess income tax benefits or deficiencies from stock-based compensation, which would be recognized as discrete items within income tax expense rather than additional paid in capital, will be offset by an equivalent adjustment to the deferred tax valuation allowance. Accordingly, adoption of this standard had no impact on our reported operations
Pronouncements Issued but Not Yet Adopted [Policy Text Block]	Pronouncements Issued but Not Yet Adopted In February 2016, FASB issued ASU No. 2016-02 – Leases (Topic 842), In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Risk Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represents approximately 33% and 40% of Clinical Services net revenue for the three months ended April 30, 2019 and 2018 respectively, and 39% for the nine months ended April 30, 2019 and 2018. As of April 30, 2019, other than the Medicare program, one provider whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 14% of Clinical Services net receivables. As of July 31, 2018, other than the Medicare program, three providers whose programs are included in either “Third-party payers” and/or “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 29% of Clinical Services net receivables.
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes and the effective tax rates for the three months ended April 30, 2019 and 2018 is $0. The provision (benefit) for income taxes for the nine months ended April 30, 2019 and 2018 is $0 and ($1,097), respectively. The effective tax rate for the nine months ended April 30, 2018 was (19.4%). The primary differences between the Company’s effective tax rates and the statutory rates for the three and nine months ended April 30, 2019 and 2018 are due to the utilization of net operating losses for which a full valuation allowance was maintained and for a tax benefit recorded in the nine month period ended April 30, 2018 of $1.1 million. The $1.1 million tax benefit in the 2018 period is due to the Tax Act, signed into law December 22, 2017, in which the legislation provided for a credit for alternative minimum taxes (AMT) paid in prior periods. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Apr. 30, 2019
Disclosure Text Block [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	The impact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in the table below: As Adjustment for New Reclassification As Restated Consolidated Statements of Operations for the three months ended April 30, 2018: Total Revenues $25,630 $(400) — $25,230 Provision for uncollectible accounts receivable 396 (400) $4 — Selling, general and administrative expenses 11,025 — (4) 11,021 Net loss $(3,016) — — $(3,016) Consolidated Statements of Operations for the nine months ended April 30, 2018: Total Revenues 80,258 (2,000) 78,258 Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Selling, general and administrative expenses 32,986 — (11) 32,975 Net loss (4,557) — — (4,557) Consolidated Statements of Cash Flows April 30, 2018: Provision for uncollectible accounts receivable 1,989 (2,000) 11 — Changes in operating assets and liabilities: Accounts receivable (1,233) 2,000 (11) 756 Consolidated balance sheet July 31, 2018: Accounts receivable 15,815 (2,523) — 13,292 Less: Allowance for doubtful accounts 2,668 (2,523) — 145 Accounts receivable, net of allowance for doubtful accounts 13,147 — — 13,147

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Apr. 30, 2019
Revenue from Contract with Customer [Abstract]
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block]	The following table represents clinical services net revenues and percentages by type of customer: Three months Three months Revenue category Third-party payer $ 5,799 50 % $ 9,965 56 % Medicare 2,634 22 2,858 16 Patient self-pay 1,881 16 2,047 12 HMO’s 1,437 12 2,867 16 Total $ 11,751 100 % $ 17,737 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 20,213 53 % $ 32,726 59 % Medicare 7,724 20 9,073 16 Patient self-pay 5,652 15 5,689 10 HMO’s 4,459 12 8,513 15 Total $ 38,048 100 % $ 56,001 100 %
Schedule of Segment Revenue By Geographical [Table Text Block]	Products revenue by geography is as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 United States $ 4,585 $ 3,987 $ 12,570 $ 11,500 Europe 1,620 1,529 4,370 4,422 Rest of the world 1,706 1,899 5,261 5,578 Total $ 7,911 $ 7,415 $ 22,201 $ 21,500

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Apr. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: April 30, July 31, Raw materials $ 895 $ 754 Work in process 2,480 2,174 Finished products 4,220 4,350 $ 7,595 $ 7,278

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the carrying amount of intangible assets, all in the Products segment is as follows: Gross Accumulated Amortization Net July 31, 2018 $ 27,347 $ (25,461 ) $ 1,886 Amortization expense — (741 ) (741 ) Foreign currency translation (110 ) 93 (17 ) April 30, 2019 $ 27,237 $ (26,109 ) $ 1,128
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite lived, consist of the following: April 30, 2019 July 31, 2018 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,992 ) $ 35 $ 11,027 $ (10,980 ) $ 47 Customer relationships 11,745 (10,652 ) 1,093 11,836 (9,997 ) 1,839 Website and acquired content 1,008 (1,008 ) — 1,008 (1,008 ) — Licensed technology and other 483 (483 ) — 483 (483 ) — Trademarks 2,974 (2,974 ) — 2,993 (2,993 ) — Total $ 27,237 $ (26,109 ) $ 1,128 $ 27,347 $ (25,461 ) $ 1,886
Schedule of Useful Lives For Acquisitions [Table Text Block]	At April 30, 2019, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8 -15 years 1 year Other intangibles 10 years 4 years

Loan Payable (Tables)

Loan Payable (Tables)	9 Months Ended
	Apr. 30, 2019
Debt Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Minimum future annual principal payments under the mortgage agreement as of April 30, 2019, are as follows: April 30, 2020 $ 134 2021 142 2022 149 2023 157 2024 165 Thereafter 3,691 4,438 Less: Current portion (134 ) Unamortized mortgage costs (69 ) Mortgage loan, non-current, net $ 4,235

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Apr. 30, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 4,848 $ 4,870 Professional fees 592 811 Legal 167 2,121 Other 2,850 2,252 $ 8,457 $ 10,054

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Apr. 30, 2019
Stockholders' Equity Note [Abstract]
Share-based Payment Arrangement, Cost by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2019 2018 2019 2018 Stock options $ 197 $ 202 $ 718 $ 609 Restricted stock 2 2 7 8 $ 199 $ 204 $ 725 $ 617
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2019 2018 2019 2018 Selling, general and administrative $ 199 $ 204 $ 725 $ 617 $ 199 $ 204 $ 725 $ 617
Share-based Payment Arrangement, Option, Activity [Table Text Block]	The following table summarizes stock option activity during the nine month period ended April 30, 2019: Options Weighted Weighted Aggregate Outstanding at July 31, 2018 1,882,116 $ 4.96 Awarded 712,821 2.81 Exercised (238,230 ) 2.69 $ 117 Cancelled or expired (3,500 ) 5.86 Outstanding at end of period 2,353,207 4.53 3.1 years $ 496 Exercisable at end of period 1,215,231 5.24 1.0 years $ 22
Schedule of Nonvested Performance-based Units Activity [Table Text Block]	The following table summarizes PSU’s granted: Period Total Fair Market Value 7/31/2018 32,000 $ 141 1/31/2019 80,500 $ 225

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Apr. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 11,751 $ 7,911 — — $ 19,662 Operating costs, expenses and legal settlements, net: Cost of revenues 10,963 3,397 — — 14,360 Research and development 31 527 $ 223 — 781 Selling, general and administrative 5,960 2,923 — $ 2,037 10,920 Legal fee expense 35 16 — 206 257 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 16,989 (22,062 ) 223 2,243 (2,607 ) Operating income (loss) (5,238 ) 29,973 (223 ) (2,243 ) 22,269 Other income (expense): Interest (18 ) 19 — 257 258 Other 6 — — 64 70 Foreign exchange loss — (332 ) — — (332 ) Income (loss) before income taxes $ (5,250 ) $ 29,660 $ (223 ) $ (1,922 ) $ 22,265 Depreciation and amortization included above $ 440 $ 340 $ — $ 58 $ 838 Share-based compensation included in above: Selling, general and administrative 40 24 — 135 199 Total $ 40 $ 24 $ — $ 135 $ 199 Capital expenditures $ 120 $ 446 $ — $ — $ 566 Three months ended April 30, 2018 Clinical Products Therapeutics Other Consolidated Revenues $ 17,737 $ 7,493 — — $ 25,230 Operating costs and expenses: Cost of revenues 10,995 3,562 — — 14,557 Research and development — 576 $ 223 — 799 Selling, general and administrative 6,252 2,970 — $ 1,799 11,021 Legal fee expense 25 19 — 1,607 1,651 Total operating costs and expenses 17,272 7,127 223 3,406 28,028 Operating income (loss) 465 366 (223 ) (3,406 ) (2,798 ) Other income (expense): Interest (22 ) 12 — 237 227 Other 15 2 — — 17 Foreign exchange loss — (462 ) — — (462 ) Income (loss) before income taxes $ 458 $ (82 ) $ (223 ) $ (3,169 ) $ (3,016 ) Depreciation and amortization included above $ 437 $ 358 $ — $ 20 $ 815 Share-based compensation included in above: Selling, general and administrative 26 17 — 161 204 Total $ 26 $ 17 $ — $ 161 $ 204 Capital expenditures $ 465 $ 96 $ — $ — $ 561 Nine months ended April 30, 2019 Clinical Products Therapeutics Other Consolidated Revenues $ 38,048 $ 22,201 — — $ 60,249 Operating costs, expenses and legal settlements, net: Cost of revenues 32,956 10,391 — — 43,347 Research and development 31 1,645 $ 666 — 2,342 Selling, general and administrative 18,220 8,828 — $ 6,339 33,387 Legal fee expense 109 24 — 2,567 2,700 Legal settlements, net — (28,925 ) — — (28,925 ) Total operating costs, expenses and legal settlements, net 51,316 (8,037 ) 666 8,906 52,851 Operating income (loss) (13,268 ) 30,238 (666 ) (8,906 ) 7,398 Other income (expense): Interest (51 ) 49 — 761 759 Other 17 — — 232 249 Foreign exchange loss (gain) — (530 ) — — (530 ) (Loss) income before income taxes $ (13,302 ) $ 29,757 $ (666 ) $ (7,913 ) $ 7,876 Depreciation and amortization included above $ 1,217 $ 1,025 $ — $ 130 $ 2,372 Share-based compensation included in above: Selling, general and administrative 118 74 — 533 725 Total $ 118 $ 74 $ — $ 533 $ 725 Capital expenditures $ 883 $ 524 $ — $ 6,147 $ 7,554 Nine months ended April 30, 2018 Clinical Products Therapeutics Other Consolidated Revenues $ 56,001 $ 22,257 — — $ 78,258 Operating costs and expenses: Cost of revenues 34,767 10,828 — — 45,595 Research and development — 1,690 $ 668 — 2,358 Selling, general and administrative 18,454 8,476 — $ 6,045 32,975 Legal fee expense 46 47 — 3,689 3,782 Total operating costs and expenses 53,267 21,041 668 9,734 84,710 Operating income (loss) 2,734 1,216 (668 ) (9,734 ) (6,452 ) Other income (expense): Interest (70 ) 35 — 604 569 Other 32 10 — 44 86 Foreign exchange loss — 143 — — 143 Income (loss) before income taxes $ 2,696 $ 1,404 $ (668 ) $ (9,086 ) $ (5,654 ) Depreciation and amortization included above $ 1,254 $ 1,039 $ — $ 57 $ 2,350 Share-based compensation included in above: Selling, general and administrative 86 61 — 470 617 Total $ 86 $ 61 $ — $ 470 $ 617 Capital expenditures $ 1,459 $ 167 $ — $ — $ 1,626

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018
Basis of Presentation (Details) [Line Items]
Minimum Estimated Material Impact On Financial Statements			$ 23,000,000
Maximum Estimated Material Impact On Financial Statements			25,000,000
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0	$ (1,097,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				19.40%
Effective Income Tax Rate Reconciliation, Tax Credit, Amount				$ 1,100,000
Clinical Services [Member] | Revenue Benchmark [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage			63.00%	72.00%
Clinical Services [Member] | Revenue Benchmark [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage	33.00%	40.00%	39.00%	39.00%
Clinical Services [Member] | Accounts Receivable [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Basis of Presentation (Details) [Line Items]
Concentration Risk, Percentage			14.00%		29.00%

Basis of Presentation (Detail_2

Basis of Presentation (Details) - Impact to consolidated statements of operations due to adoption of ASU - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Revenues	$ 19,662	$ 25,230	$ 60,249	$ 78,258
Selling, general and administrative expenses	10,920	11,021	33,387	32,975
Net loss	22,265	(3,016)	7,876	(4,557)
Consolidated Statements of Cash Flows April 30, 2018:
Changes in operating assets and liabilities: Accounts receivable			1,605	756
Consolidated balance sheet July 31, 2018:
Accounts receivable					$ 13,292
Less: Allowance for doubtful accounts					145
Accounts receivable, net of allowance for doubtful accounts	$ 11,441		$ 11,441		13,147
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Revenues		25,630		80,258
Provision for uncollectible accounts receivable		396		1,989
Selling, general and administrative expenses		11,025		32,986
Net loss		(3,016)		(4,557)
Consolidated Statements of Cash Flows April 30, 2018:
Provision for uncollectible accounts receivable				1,989
Changes in operating assets and liabilities: Accounts receivable				(1,233)
Consolidated balance sheet July 31, 2018:
Accounts receivable					15,815
Less: Allowance for doubtful accounts					2,668
Accounts receivable, net of allowance for doubtful accounts					13,147
Accounting Standards Update 2014-09 [Member] | Restatement Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Revenues		(400)		(2,000)
Provision for uncollectible accounts receivable		(400)		(2,000)
Consolidated Statements of Cash Flows April 30, 2018:
Provision for uncollectible accounts receivable				(2,000)
Changes in operating assets and liabilities: Accounts receivable				2,000
Consolidated balance sheet July 31, 2018:
Accounts receivable					(2,523)
Less: Allowance for doubtful accounts					$ (2,523)
Accounting Standards Update 2014-09 [Member] | Reclassification Of Residual [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Provision for uncollectible accounts receivable		4		11
Selling, general and administrative expenses		$ (4)		(11)
Consolidated Statements of Cash Flows April 30, 2018:
Provision for uncollectible accounts receivable				11
Changes in operating assets and liabilities: Accounts receivable				$ (11)

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Unvested Restricted Stock [Member] | In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		431,000		694,000
Outstanding Options [Member] | Out of the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,640,000	581,000	1,541,000	194,000

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Third Party Payer And Health Maintenance Organizations [Member] | Minimum [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period			60 days
Third Party Payer And Health Maintenance Organizations [Member] | Maximum [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period			90 days
Government Payer Medicare [Member]
Revenue Recognition (Details) [Line Items]
Billing Information Filing Deadline Period			60 days
Patient self-pay [Member]
Revenue Recognition (Details) [Line Items]
Billing Period			210 days
Receivable Collection Period			180 days
Products Revenue And Royalty Income [Member]
Revenue Recognition (Details) [Line Items]
Claim Period For Return Of Goods			30 days
Royalty Income, Nonoperating (in Dollars)	$ 0	$ 78,000	$ 0	$ 639,000
Products Revenue And Royalty Income [Member] | Minimum [Member]
Revenue Recognition (Details) [Line Items]
Receivable Collection Period			30 days
Products Revenue And Royalty Income [Member] | Maximum [Member]
Revenue Recognition (Details) [Line Items]
Receivable Collection Period			90 days
Clinical Services [Member] | Revenue Benchmark [Member]
Revenue Recognition (Details) [Line Items]
Concentration Risk, Percentage			63.00%	72.00%
Clinical Services [Member] | Revenue Benchmark [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Revenue Recognition (Details) [Line Items]
Concentration Risk, Percentage	33.00%	40.00%	39.00%	39.00%

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer - Clinical Services [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer [Line Items]
Revenue Services Net	$ 11,751	$ 17,737	$ 38,048	$ 56,001
Revenue Services Net Percentage	100.00%	100.00%	100.00%	100.00%
Third-Party Payer [Member]
Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer [Line Items]
Revenue Services Net	$ 5,799	$ 9,965	$ 20,213	$ 32,726
Revenue Services Net Percentage	50.00%	56.00%	53.00%	59.00%
Medicare [Member]
Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer [Line Items]
Revenue Services Net	$ 2,634	$ 2,858	$ 7,724	$ 9,073
Revenue Services Net Percentage	22.00%	16.00%	20.00%	16.00%
Patient self-pay [Member]
Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer [Line Items]
Revenue Services Net	$ 1,881	$ 2,047	$ 5,652	$ 5,689
Revenue Services Net Percentage	16.00%	12.00%	15.00%	10.00%
HMO’s [Member]
Revenue Recognition (Details) - Schedule of net revenues and percentages by type of customer [Line Items]
Revenue Services Net	$ 1,437	$ 2,867	$ 4,459	$ 8,513
Revenue Services Net Percentage	12.00%	16.00%	12.00%	15.00%

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of product revenue by geography - Life Sciences [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Revenue Recognition (Details) - Schedule of product revenue by geography [Line Items]
Products revenue	$ 7,911	$ 7,415	$ 22,201	$ 21,500
UNITED STATES
Revenue Recognition (Details) - Schedule of product revenue by geography [Line Items]
Products revenue	4,585	3,987	12,570	11,500
Europe [Member]
Revenue Recognition (Details) - Schedule of product revenue by geography [Line Items]
Products revenue	1,620	1,529	4,370	4,422
Rest of world [Member]
Revenue Recognition (Details) - Schedule of product revenue by geography [Line Items]
Products revenue	$ 1,706	$ 1,899	$ 5,261	$ 5,578

Supplemental disclosure for s_2

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Income Taxes Paid			$ 94	$ 65
Interest Paid			138	61
Capital Lease Obligation Cost Basis			$ 381	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)			238,230
Stock Issued During Period, Value, Employee Benefit Plan	$ 832	$ 782	$ 832	$ 782
Directors And Officers [Member]
Supplemental disclosure for statement of cash flows (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	203,511		203,511
Stock Issued During Period Shares Stock Options Exercised1 (in Shares)	23,376		23,376

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Schedule of inventory, current [Abstract]
Raw materials	$ 895	$ 754
Work in process	2,480	2,174
Finished products	4,220	4,350
	$ 7,595	$ 7,278

Goodwill and intangible asset_2

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Clinical Services [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452

Goodwill and intangible asset_3

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - Products [Member] $ in Thousands	9 Months Ended
	Apr. 30, 2019USD ($)
Indefinite-lived Intangible Assets [Line Items]
Gross, Beginning Balance	$ 27,347
Accumulated Amortization, Beginning Balance	(25,461)
Net, Beginning Balance	1,886
Amortization expense, Accumulated Amortization	(741)
Amortization expense, Net	(741)
Foreign currency translation, Gross	(110)
Foreign currency translation, Accumulated Amortization	93
Foreign currency translation, Net	(17)
Gross, Ending Balance	27,237
Accumulated Amortization, Ending Balance	(26,109)
Net, Ending Balance	$ 1,128

Goodwill and intangible asset_4

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,237	$ 27,347
Finite-lived intangible assets, Accumulated Amortization	(26,109)	(25,461)
Finite-lived intangible assets, Net	1,128	1,886
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,992)	(10,980)
Finite-lived intangible assets, Net	35	47
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,745	11,836
Finite-lived intangible assets, Accumulated Amortization	(10,652)	(9,997)
Finite-lived intangible assets, Net	1,093	1,839
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,008	1,008
Finite-lived intangible assets, Accumulated Amortization	(1,008)	(1,008)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	483	483
Finite-lived intangible assets, Accumulated Amortization	(483)	(483)
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	2,974	2,993
Finite-lived intangible assets, Accumulated Amortization	$ (2,974)	$ (2,993)

Goodwill and intangible asset_5

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	9 Months Ended
	Apr. 30, 2019
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	1 year
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	4 years
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Loan Payable (Details)

Loan Payable (Details) - Mortgage Agreement [Member] - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Nov. 27, 2018	Apr. 30, 2019
Loan Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 4,500
Debt Instrument Maturity Period		10 years
Debt Instrument, Interest Rate, Stated Percentage	5.09%
Debt Instrument, Periodic Payment	$ 30
Amortization of Debt Issuance Costs	$ 72
Unamortized Debt Issuance Expense		$ 69
Operating Leases, Future Minimum Payments Due		4,438
Cash Collateral for Borrowed Securities		$ 750

Loan Payable (Details) - Schedu

Loan Payable (Details) - Schedule of future annual principal payments - Mortgage Agreement [Member] $ in Thousands	Apr. 30, 2019USD ($)
Loan Payable (Details) - Schedule of future annual principal payments [Line Items]
2020	$ 134
2021	142
2022	149
2023	157
2024	165
Thereafter	3,691
	4,438
Less: Current portion	(134)
Unamortized mortgage costs	(69)
Mortgage loan, non-current, net	$ 4,235

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of Accrued liabilities - USD ($) $ in Thousands	Apr. 30, 2019	Jul. 31, 2018
Schedule of Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 4,848	$ 4,870
Professional fees	592	811
Legal	167	2,121
Other	2,850	2,252
	$ 8,457	$ 10,054

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jan. 05, 2018	Apr. 30, 2019	Apr. 30, 2018	Jan. 31, 2019	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018	Dec. 31, 2014	Jan. 14, 2011
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.01			$ 0.01		$ 0.01
Percentage of Commission Payable on Equity Offering					3.00%
Maximum Offering Price Under Sales Agreement (in Dollars)		$ 20,000,000			$ 20,000,000			$ 20,000,000
Excess Tax Benefit from Share-based Compensation, Financing Activities (in Dollars)					0	$ 0
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)		1,200,000			$ 1,200,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					17 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					238,230
Stock Issued During Period, Value, Employee Benefit Plan (in Dollars)		$ 832,000	$ 782,000		$ 832,000	782,000
Performance Shares [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		1,628			1,628
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in Dollars per share)		$ 6			$ 6
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount (in Dollars)		$ 10,000			$ 10,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms					21 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					985
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)					$ 4,000
Stock Issued During Period, Value, Employee Benefit Plan (in Dollars)					$ 832,000	$ 782,000
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	5,000,000								3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,222,000			1,222,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Authorized Common Stock That May Be Issued And Sold Under Sales Agreement (in Dollars)							$ 19,150,000
Securities That May Be Sold Under The Agreement (in Dollars)							$ 150,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			46,022		34,719	274,726
Stock Issued During Period Shares Stock Options Exercised1					23,376
Stock Issued During Period, Value, Employee Benefit Plan (in Dollars)		$ 3,000			$ 3,000
Stock Issued During Period, Shares, Employee Benefit Plan		315,472	37,580		315,472	37,580
Treasury Stock, Shares, Acquired						340,898
Common Stock [Member] | Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Employee Benefit Plan					315,472	37,580
Treasury Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Value, Employee Benefit Plan (in Dollars)			$ 1,014,000			$ 1,014,000
Stock Issued During Period, Shares, Employee Benefit Plan			(106,911)			(106,911)
Treasury Stock, Shares, Acquired						106,911
Treasury Stock [Member] | Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Treasury Stock, Shares, Acquired						106,911
Directors And Officers [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		203,511			203,511
Stock Issued During Period Shares Stock Options Exercised1		23,376			23,376
Executive Officer [Member] | Performance Shares [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				80,500			32,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)				$ 225,000			$ 141,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Share-based compensation expense	$ 199	$ 204	$ 725	$ 617
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Share-based compensation expense	197	202	718	609
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Share-based compensation expense	$ 2	$ 2	$ 7	$ 8

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement	$ 199	$ 204	$ 725	$ 617
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement	$ 199	$ 204	$ 725	$ 617

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of stock option plans - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2019
Schedule of stock option plans [Abstract]
Outstanding, Options at July 31, 2018	1,882,116
Outstanding, Weighted Avarage Exercise Price at July 31, 2018	$ 4.96
Awarded, Options	712,821
Awarded, Weighted Avarage Exercise Price	$ 2.81
Exercised, Options	(238,230)
Exercised, Weighted Avarage Exercise Price	$ 2.69
Exercised, Aggregate Intrinsic Value	$ 117
Cancelled or expired, Options	(3,500)
Cancelled or expired, Weighted Avarage Exercise Price	$ 5.86
Outstanding, Options at end of period	2,353,207
Outstanding, Weighted Avarage Exercise Price at end of period	$ 4.53
Outstanding, Weighted Average Remaining Contractual Term	3 years 36 days
Outstanding, Aggregate Intrinsic Value	$ 496
Exercisable, Options at end of period	1,215,231
Exercisable, Weighted Avarage Exercise Price at end of period	$ 5.24
Exercisable, Weighted Average Remaining Contractual Term	1 year
Exercisable, Aggregate Intrinsic Value	$ 22

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Shedule of performance stock units activity - Executive Officer [Member] - Performance Shares [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jan. 31, 2019	Jul. 31, 2018
Stockholders' Equity (Details) - Shedule of performance stock units activity [Line Items]
Total Grant	80,500	32,000
Fair Market Value Grant Date	$ 225	$ 141

Segment reporting (Details)

Segment reporting (Details)	9 Months Ended
	Apr. 30, 2019
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Clinical Services [Member]
Segment Reporting Information [Line Items]
Revenues	$ 11,751	$ 17,737	$ 38,048	$ 56,001
Cost of revenues	10,963	10,995	32,956	34,767
Research and development	31		31
Selling, general and administrative	5,960	6,252	18,220	18,454
Legal fee expense	35	25	109	46
Total operating costs and expenses	16,989	17,272	51,316	53,267
Operating income (loss)	(5,238)	465	(13,268)	2,734
Interest	(18)	(22)	(51)	(70)
Other	6	15	17	32
Income (loss) before income taxes	(5,250)	458	(13,302)	2,696
Depreciation and amortization included above	440	437	1,217	1,254
Capital expenditures	120	465	883	1,459
Clinical Services [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	40	26	118	86
Clinical Services [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	40	26	118	86
Products [Member]
Segment Reporting Information [Line Items]
Revenues	7,911	7,493	22,201	22,257
Cost of revenues	3,397	3,562	10,391	10,828
Research and development	527	576	1,645	1,690
Selling, general and administrative	2,923	2,970	8,828	8,476
Legal fee expense	16	19	24	47
Legal settlements, net	(28,925)		(28,925)
Total operating costs and expenses	(22,062)	7,127	(8,037)	21,041
Operating income (loss)	29,973	366	30,238	1,216
Interest	19	12	49	35
Other		2		10
Foreign exchange loss (gain)	(332)	(462)	(530)	143
Income (loss) before income taxes	29,660	(82)	29,757	1,404
Depreciation and amortization included above	340	358	1,025	1,039
Capital expenditures	446	96	524	167
Products [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	24	17	74	61
Products [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	24	17	74	61
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues	19,662	25,230	60,249	78,258
Cost of revenues	14,360	14,557	43,347	45,595
Research and development	781	799	2,342	2,358
Selling, general and administrative	10,920	11,021	33,387	32,975
Legal fee expense	257	1,651	2,700	3,782
Legal settlements, net	(28,925)		(28,925)
Total operating costs and expenses	(2,607)	28,028	52,851	84,710
Operating income (loss)	22,269	(2,798)	7,398	(6,452)
Interest	258	227	759	569
Other	70	17	249	86
Foreign exchange loss (gain)	(332)	(462)	(530)	143
Income (loss) before income taxes	22,265	(3,016)	7,876	(5,654)
Depreciation and amortization included above	838	815	2,372	2,350
Capital expenditures	566	561	7,554	1,626
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	199	204	725	617
Consolidated [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	199	204	725	617
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	223	223	666	668
Total operating costs and expenses	223	223	666	668
Operating income (loss)	(223)	(223)	(666)	(668)
Income (loss) before income taxes	(223)	(223)	(666)	(668)
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	2,037	1,799	6,339	6,045
Legal fee expense	206	1,607	2,567	3,689
Total operating costs and expenses	2,243	3,406	8,906	9,734
Operating income (loss)	(2,243)	(3,406)	(8,906)	(9,734)
Interest	257	237	761	604
Other	64		232	44
Income (loss) before income taxes	(1,922)	(3,169)	(7,913)	(9,086)
Depreciation and amortization included above	58	20	130	57
Capital expenditures			6,147
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	135	161	533	470
Other Segments [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	$ 135	$ 161	$ 533	$ 470

Contingencies (Details)

Contingencies (Details) $ in Thousands	Feb. 05, 2019USD ($)	Apr. 30, 2019USD ($)	Apr. 30, 2019USD ($)
Contingencies (Details) [Line Items]
Number Of Pending Cases			3
Gain (Loss) Related to Litigation Settlement	$ 19,400	$ 28,925	$ 28,925
Roche [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount Awarded from Other Party	$ 21,000
Hologic Inc [Member]
Contingencies (Details) [Line Items]
Litigation Settlement, Amount Awarded from Other Party		14,000
Gain (Loss) Related to Litigation Settlement		$ 9,500